Vadivelu N, Stephen D C, Kanagasabapathy A S, Seshadri M S
Department of Clinical Biochemistry, Christian Medical College & Hospital, Vellore.
Indian J Med Res. 1990 Aug;92:220-3.
Thyroid stimulating hormone receptor antibody (TRA) was estimated as a measure of TSH binding inhibitory immunoglobulin (TBII) in 48 persons. These included (i) 14 controls; (ii) 23 patients with Graves' disease who were tested for TRA within 3 months of commencing treatment with carbimazole of which 13 were studied serially; (iii) 5 patients with toxic nodular goitre; (iv) 4 with euthyroid exophthalmos; and (v) 2 neonates of thyrotoxic mothers. TRA was measured with an RIA system, while total thyroxine (T4), free thyroxine concentration (FTC) and TSH were also estimated along with TRA. All controls showed undetectable TRA levels; 87 per cent of patients with Graves' disease were TRA positive within 3 months of starting carbimazole therapy. In the serial study, 5 patients with Graves' disease who had undetectable TRA initially remained so while on treatment. Seven out of the remaining 8 patients showed a decline of TRA levels to normal over 3 to 18 months. This decline coincided with clinical and biochemical recovery.
在48人中对促甲状腺激素受体抗体（TRA）进行了评估，以此作为促甲状腺激素结合抑制性免疫球蛋白（TBII）的一项指标。这些人包括：（i）14名对照者；（ii）23名格雷夫斯病患者，在开始使用卡比马唑治疗的3个月内检测TRA，其中13人进行了连续研究；（iii）5名毒性结节性甲状腺肿患者；（iv）4名甲状腺功能正常的突眼症患者；以及（v）2名甲状腺毒症母亲的新生儿。TRA采用放射免疫分析系统进行测量，同时还对总甲状腺素（T4）、游离甲状腺素浓度（FTC）和TSH以及TRA进行了评估。所有对照者的TRA水平均检测不到；87%的格雷夫斯病患者在开始卡比马唑治疗的3个月内TRA呈阳性。在连续研究中，5名最初TRA检测不到的格雷夫斯病患者在治疗期间仍保持该状态。其余8名患者中有7名在3至18个月内TRA水平降至正常。这种下降与临床和生化指标的恢复同时出现。
